Original language | English (US) |
---|---|
Pages (from-to) | 3991-3995 |
Number of pages | 5 |
Journal | Blood Advances |
Volume | 6 |
Issue number | 13 |
DOIs | |
State | Published - Jul 12 2022 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood Advances, Vol. 6, No. 13, 12.07.2022, p. 3991-3995.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma
AU - Kansagra, Ankit
AU - Dispenzieri, Angela
AU - Fraser, Raphael
AU - Estrada-Merly, Noel
AU - Sidana, Surbhi
AU - Nishihori, Taiga
AU - Hansen, Doris K.
AU - Anderson, Larry D.
AU - Banerjee, Rahul
AU - Bumma, Naresh
AU - Dhakal, Binod
AU - Khouri, Jack
AU - Landau, Heather
AU - Lee, Cindy
AU - Mian, Hira
AU - Nathan, Sunita
AU - Savani, Bipin
AU - Kumar, Shaji
AU - Qazilbash, Muzaffar
AU - Shah, Nina
AU - D'Souza, Anita
N1 - Funding Information: Oncopeptides, Beigene, Antengene, and GLH Pharma. M.Q. reports research funding from Janssen, NeXimmune, Angiocrine, Bioline, and Amgen, participation on an advisory board from Onco-peptides, and participation on a data safety monitoring board with Autolus. A. D’Souza reports research funding from Takeda, TeneoBio, Janssen, Sanofi, Regeneron, Prothena, and Caelum; board membership for BMS, Imbrium, Pfizer, and Prothena; and consultancy with Janssen. The remaining authors declare no competing financial interests. Funding Information: Conflict-of-interest disclosure: A.K. reports consulting fees from Abbvie, Alynylam, BMS, Cota Health, GSK, Janssen, Oncopeptide, and Takeda. S.S. reports research funding from Magenta Therapeutics, BMS, Allogene, and Janssen and consultancy with Magenta Therapeutics, BMS, Janssen, Sanofi, and Oncopeptides. T.N. reports clinical trial support to the institution from Novartis and clinical trial support (drug only supply) to the institution from Kayto-pharm. D.K.H. reports financial relationships within the past 12 months from OncLive (honoraria). L.D.A. reports financial relationships within the 36 months at UTSW with GSK (research grants), Janssen (research grants), BMS (research grants), Celgene (research grants), and Karyopharm (research grants); consulting fees and advisory board activity with GSK, Janssen, BMS, Celgene, Amgen, Oncopeptides, Karyopharm, and Prothena; and limits income to under 5K per company per year; DSMB: Prothena. R.B. reports financial relationships within the past 36 months with Sanofi (consulting), SparkCures (consulting), Guidepoint Global (consulting), Pack Health (institutional research funding), and University of California (employment). N.B. reports consultancy with Jansse and Sanofi and speaker bureau Amgen, Sanofi, and Oncopeptides. H.L. reports research support from Takeda; consulting fees from Pro-thena and Karyopharm; payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing, or education events from Sanofi/Genzyme; and participation on a data safety monitoring board or advisory board for BMS/Celgene, Janssen, Takeda, Caelum Biosciences, Karyopharm, Sanofi/Genzyme, and Pfizer. J.K. reports financial relationships within the past 36 months from OncLive (honoraria). B.D. reports financial relationships within the past 36 months with Celegene/BMS (honorarium), GSK (honorarium), and Karyopharm (honorarium) and has served as an advisory board member for Janssen, Arcellx, Natera, GSK, Amgen, and Takeda. C.L. reports advisory board membership with Janssen and BMS. H.M. reports having received research grant from Janssen and advisory board fees from BMS/Celgene, Takeda, Janssen, Amgen, GSK, and Sanofi. S.K. reports research funding for clinical trials to Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio, and Molecular Templates; consulting/advisory board participation (with no personal payments) for Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeu-tics, Monterosa therapeutics, Trillium, and (with personal payment) Funding Information: Acknowledgments: The Center for International Blood and Marrow Transplant Research (CIBMTR) is supported primarily by Public Health Service U24CA076518 from National Institutes of Health (NIH) National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research. Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Accenture Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Astellas Pharma US; Bluebird Bio, Inc.; Bristol Myers Squibb Co.; CareDx; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Euro-fins Viracor; DBA Eurofins Transplant Diagnostics; Fate Therapeutics; Gamida-Cell, Ltd.; Gilead; GlaxoSmithKline; HistoGenetics; Incyte Corporation; Iovance; Janssen Research & Development, LLC; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Kadmon; Karius; Karyopharm Therapeutics; Kiadis Pharma; Kite Pharma Inc; Kite, a Gilead Company; Kyowa Kirin International plc; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Medac GmbH; Medexus,; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; OncoIm-mune, Inc.; Oncopeptides, Inc.; OptumHealth; Orca Biosystems, Inc.; Ossium Health, Inc; Pfizer, Inc.; Pharmacyclics, LLC; Prio-thera; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Talaris Therapeutics; Terumo Blood and Cell Technologies; TG Therapeutics; Tscan; Vertex; Vor Biopharma; and Xenikos BV.
PY - 2022/7/12
Y1 - 2022/7/12
UR - http://www.scopus.com/inward/record.url?scp=85134538302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134538302&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2022007218
DO - 10.1182/bloodadvances.2022007218
M3 - Letter
C2 - 35507742
AN - SCOPUS:85134538302
SN - 2473-9529
VL - 6
SP - 3991
EP - 3995
JO - Blood Advances
JF - Blood Advances
IS - 13
ER -